Drug Trial Radar · NCT05320380
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Last checked: Nov 19, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 1, 2023
Primary completion
Sep 1, 2023
Study completion Sep 1, 2023
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- ImmunoGen, Inc.; National Cancer Institute (NCI)
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial finds the highest safe dose of IMGN632 that can be given with other chemotherapy without causing severe side effects, studies what kind of side effects IMGN632 may cause, and determines whether IMGN632 is a beneficial treatment for leukemia in children that has come back after treatment or is difficult to treat. IMGN632 is a monoclonal antibody linked to a chemotherapy drug. IMGN632 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD123 receptors, and delivers the chemotherapy drug to kill them. Giving IMGN632 with other chemotherapy may cause the leukemia to stop growing or to shrink for a period of time.
Conditions
- Recurrent Acute Myeloid Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Mixed Phenotype Acute Leukemia
- Recurrent T Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Mixed Phenotype Acute Leukemia
- Refractory T Acute Lymphoblastic Leukemia
Interventions
Anti-CD123 ADC IMGN632Drug
Given IV
Bone Marrow Aspiration and BiopsyProcedure
Undergo bone marrow aspiration/biopsy
CytarabineDrug
Given IT and IV
Fludarabine PhosphateDrug
Given IV
Hydrocortisone Sodium SuccinateDrug
Given IT
Liposome-encapsulated Daunorubicin-CytarabineDrug
Given IV
MethotrexateDrug
Given IT
PrednisoloneDrug
Given IT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase 2 dose (RP2D) of IMGN632 monotherapy (Cohort 1)Time frame: During cycle 1 (Each cycle = 42 days)
- Flow-based overall response rate (ORR) (Cohort 1)Time frame: During cycle 1 (Each cycle = 42 days)
- RP2D of combination therapy (Cohort 2)Time frame: During cycle 1 (Each cycle = 42 days)
- Minimal residual disease (MRD) negative flow-based ORR (Cohort 3)Time frame: Up to two cycles of IMGN632 with chemotherapy (Each cycle = 42 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.